Analysts Offer Insights on Healthcare Companies: Equillium (EQ), UnitedHealth (UNH) and Arcus Biosciences (RCUS)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Equillium (EQ), UnitedHealth (UNH) and Arcus Biosciences (RCUS) with bullish sentiments.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Equillium (EQ)
Roth MKM analyst Adam Walsh reiterated a Buy rating on Equillium today and set a price target of $12.00. The company’s shares closed last Monday at $2.01.
According to TipRanks.com, Walsh is a 4-star analyst with an average return of
Equillium has an analyst consensus of Strong Buy, with a price target consensus of $7.80, representing a 282.4% upside. In a report issued on April 7, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
UnitedHealth (UNH)
In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on UnitedHealth, with a price target of $411.00. The company’s shares closed last Monday at $323.48.
According to TipRanks.com, Wilkes is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $367.81 average price target, a 13.5% upside from current levels. In a report issued on April 7, Wells Fargo also maintained a Buy rating on the stock with a $370.00 price target.
Arcus Biosciences (RCUS)
In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on Arcus Biosciences, with a price target of $41.00. The company’s shares closed last Monday at $22.74.
According to TipRanks.com, Driscoll is a 4-star analyst with an average return of
Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $36.25, representing a 49.7% upside. In a report released yesterday, Leerink Partners also maintained a Buy rating on the stock with a $47.00 price target.
Read More on EQ:
